White Papers
October 6, 2026

E-invoicing Beyond Finance: Why Supply Chain Matters

By Corné van Raak and Jordy Snijders

E-invoicing is not simply a finance initiative. Its implications reach across the organization, touching supply chain operations, logistics partnerships, IT systems, and master data management. As invoices are the financial representation of the physical flow of goods, supply chain is not just a stakeholder, but an essential one. Successful e-invoicing programs therefore require close collaboration between supply chain, finance, tax, IT, and other business functions.

This paper examines e-invoicing from an organizational perspective, why cross-functional ownership matters, and how organizations can structure their approach to implementation. It also assesses the role of third-party logistics providers, introduces a practical assessment framework for evaluating organizational preparedness, and provides an updated overview of e-invoicing requirements and implementation timelines across the EU4 pharmaceutical markets.

Request a Copy

White Papers
September 21, 2026

Protection that Holds: Planning for Disruption in Pharma Supply Chains

By Daniel Schnitzler

Supply chain resilience has become a board-level topic. Drug shortages have made fragility visible to executives and patients. Tariffs have made single-sourcing expensive as well as risky. And regulators now treat security of supply as an obligation rather than good practice. Yet most companies already invest in resilience, and disruptions still catch them out, because protection that looked solid on paper fails when it is needed.

This paper explains why, and what to do about it, in three steps:

1.   Map the Exposure

2.   Design for Disruption

3.   Operate It as Routine

The paper closes with six priority actions for supply chain leaders.

Request a Copy

White Papers
May 28, 2026

From Defense to Offense: A New Paradigm for Life Science Supply Chains

By Thomas Ebel

The life science industry is innovating at an unprecedented pace, but its supply chains are struggling to keep up. Built for an era of stability, predictability, and incremental change, today’s supply chain model is no longer sufficient. What is needed now is an approach that moves from defense to offense: strategically integrated with the business, built for adaptability, and focused on creating value rather than merely managing operational efficiency.

This paper explores the structural shifts reshaping the industry and outlines an operating model to help organizations master this transition across five key capabilities: Business Integration, Planning Philosophy, Process Logic, External Signals, and Measures of Success and Value Creation. It concludes with five priority actions for supply chain leaders seeking to make the shift from reactive execution to strategic shaping.

Request a Copy

last mile white paper

White Papers
December 10, 2025

Designing the Last Mile: A Strategic Framework for Biopharma Launch Distribution

By Arthur Mendonca, Peter Martens, and Ronald van Zitteren

Success in pharmaceutical product launches hinges not just on regulatory approvals and market access, but increasingly on how efficiently and reliably a product reaches its end user.

Understanding the “last mile” from a distribution and supply chain perspective is essential to inform the strategic, operational, and tactical model for final product delivery. The last mile involves delivering a product from a manufacturer’s central or local distribution location to the point of dispense or use, and for novel therapies it must align the needs of patients and HCPs with product logistics and regulatory requirements.


Rather than treating the last mile as merely a logistics problem, a systematic approach transforms distribution complexity into strategic advantage. This white paper presents AIM’s four-step framework for last mile design, showing how structured stakeholder engagement and strategic analysis enable companies to build distribution models on validated insights rather than assumptions.

Request a Copy

White Papers
October 30, 2021

Webinar Summary – Launching a First Product in Europe: The Supply Chain Perspective

On 27 October 2021, AIM hosted a webinar panel discussion that addressed the key supply chain aspects associated with launching a new pharmaceutical or biotech therapy in Europe.

Our panel of experts included:

  • Pim Van Der Aar, Co-Founder & Managing Director, AIM (Moderator)
  • Christian Ellereit, Head of Finance, Europe, Travere Therapeutics
  • Ronald van Zitteren, Principal, AIM
  • Joop Wijdeven, Associate, AIM

The panelists covered supply chain key success factors, best practices, and common pitfalls and mistakes. They also discussed key licensing and legal requirements, as well as the main steps involved in designing and implementing a life science supply chain in Europe. This paper provides a written summary of the webinar.

Request a Copy